Resources
32 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Medication Assisted Treatment (MAT) for Opioid Use Disorder: Philosophical and Practical Considerations Webinar Presentation and Materials
Posted 12/30/2019 (updated 3/28/2024)
Pharmacotherapy of Opioid Use Disorder Webinar Presentation and Resources
Posted 9/4/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy and Learning Collaborative Orientation Webinar took place on August 25, 2020. Please find the presentation and recording posted here.
Posted 9/14/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy Town Hall took place on September 1, 2020.
Please find the presentation and recording posted here.
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 12/15/2020 (updated 4/3/2024)
Dr. Seale led a discussion on communicating OUD needs in your community, building MOUD practice capacity, and other considerations and lessons learned from his work with individuals in rural communities.
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 8/4/2021 (updated 4/2/2024)